Aligos Therapeutics earnings were -$74.2M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest ALGS earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$15.9M, down 136.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ALGS reported annual earnings of -$131.2M, with 49.6% growth.
Aligos Therapeutics Earnings Reports & History FAQ
What were Aligos Therapeutics's earnings last quarter?
Aligos Therapeutics (NASDAQ: ALGS) reported Q2 2025 earnings per share (EPS) of -$1.53, up 288.89% year over year. Total ALGS earnings for the quarter were -$15.86 million. In the same quarter last year, Aligos Therapeutics's earnings per share (EPS) was $0.81.
Is Aligos Therapeutics profitable or losing money?
As of the last Aligos Therapeutics earnings report, Aligos Therapeutics is currently losing money. Aligos Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$74.18 million, a 2.05% decrease year over year.
What was ALGS's earnings growth in the past year?
As of Aligos Therapeutics's earnings date in Q3 2025, Aligos Therapeutics's earnings has grown year over year. ALGS earnings in the past year totalled -$74.18 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.